Systematic review on epstein-barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in asian populations

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2577-2581

  Han, Bao Lin ^a   Xu, Xiang Ying ^a   Zhang, Chun Zhi ^b   Wu, Jian Juan ^b   Han, Chun Feng ^a   Wang, Hui ^a   Wang, Xuan ^a   Wang, Guang Shun ^a   Yang, Shu Juan ^c   Xie, Yao ^c  

^a Tianjin Baodi Hospital   (China)

^b TIANJIN HUANHU HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Epstein Barr virus (EBV) DNA, diagnosis, nasopharyngeal carcinoma, Asian population

Indexed keywords

EID: 84874099682     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2577     Document Type: Article

References (35)

1. Chan ATC, Lo YMD, Zee B, et al(2002). Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst, 94, 1614-9.
2. Chang KP, Hsu CL, Chang YL, et al(2008). Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol, 44, 784-92.
3. Chan KCA, Lo YMD (2002). Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Cancer Biol, 12, 489-96.
4. Chan KH, Gu YL, Ng F, et al(2003). EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer, 105, 706-9.
5. Fan H, Nicholls J, Chua D, et al(2004). Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer, 112, 103641.
6. Feng HY, Huang YJ, Zhou XY, et al(2009). Diagnosis of NPC with Plasma EBV DNA. Journal of Tropical Medicine, 9, 913-5.
7. Kong P (2010). The clinical value of the quantitative determination of EBV-DNA in blood serum and PBMC patients with nasopharyngeal carcinoma. J Shandong Med College, 32, 321-4.
8. Leung SF, Tam JS, Chan AT, et al(2004). Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem, 50, 339-45.
9. Liao LY, Kong M, Liu CJ (2010). Comparison of detection of white blood cell's EBV DNA and plasma's VCA-IgA in nasopharyngeal carcinoma patients. Med Innov China, 7, 145-6.
10. Lin JC, Chen KY, Wang WY, et al(2001). Detection of Epstein- Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol, 19, 2607-15.
11. Lo YMD, Chan LY, Chan AT, et al(1999). Quantitative and temporal correlation between circulating cell-free Epstein- Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res, 59, 5452-5.
12. Lo YMD, Chan LYS, Lo KW, et al(1999). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59, 1188-99.
13. Lo YMD, Leung S, Chan LY, et al(2000). Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res, 60, 2351-5.
14. Luo YL, Ou GP, Chi PD, et al(2009). Combined determination of Epstein-barr virus related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Chinese Journal of China, 28, 96-9.
15. Mai S, Zong Y, Zhang M, et al(2002). Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma. Chin Med J, 115, 1895-7.
16. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al(1998). Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res, 4, 665-9.
17. Ng WT, Choi CW, Lee MC, et al(2010). Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer, 9, 221-8.
18. Shao JY, Zhang Y, Li YH, et a1(2004). Comparison of Epstein- Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res, 24, 4059-66.
19. Sharma TD, Singh TT, Laishram RS, et al(2011).Nasopharyngeal carcinoma--a clinico-pathological study in a regional cancer centre of northeastern India. Asian Pac J Cancer Prev, 12, 1583-7.
20. Shotelersuk K, Khorprasert C, Sakdikul S, et al(2000). Epstein- Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res, 6, 1046 -51.
21. Sun JG, Wang HX, Xiao FG, et al(2010). Clinical application of plasma ell free EBV DNA, serum CYFR A21-1 and VCA-IgA in patients with nasopharyngeal carcinoma. Modern Oncology, 18, 1930-2.
22. Sun JG, Zheng AP (2008). Clinical significance of plasma EBV DNA and VCA-IgA for nasopharyngeal carcinoma. Modern Oncol, 16, 2086-7.
23. Parkin DM, Bray F, Ferlay J, et al(2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
24. Tan YJ, Su XK, Cui JH (2010). Comparison of detection of serum VCA-lgA, EA-IgA and EBV-DNA in nasopharyngeal carcinoma patient. Chongqing Med J, 39, 703-6.
25. Tsang RK, Vlantis AC, Ho RW, et al(2004). Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck, 26, 598-602.
26. Wei K, Xu Y, Liu J, Zhang W, Liang Z (2010). No incidence trends and no change in pathological proportions of nasopharyngeal carcinoma in Zhongshan in 1970-2007. Asian Pac J Cancer Prev, 11, 1595-9.
27. Wei WI, Sham JS, Zong YS, et al(1991). The efficacy of fiberoptic endoscopic examination and biopsy in the detection of early nasopharyngeal carcinoma. Cancer, 67, 3127-30.
28. Yang X, Goldstein AM, Chen CJ (2006). Distribution of Epstein- Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer, 118, 780-4.
29. Zeng Y, Zhang LG, Li HY, et al(1982). Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer, 29, 139-41.
30. Zeng Y, Zhang LG, Wu YC, et al(1985). Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/ VCA antibody-positive persons in Wuzhou City, China. Int J Cancer, 36, 545-7.
31. Zeng Y, Zhong JM, Li LY, et al(1983). Follow-up studies on Epstein-Barr virus IgA/ VCA antibody-positive persons in Zangwu County, China. Intervirology, 20, 1990-4.
32. Zhang LW, Luo BQ, Dou XQ, et al(2012). Quantitative analysis of Epstein-Barr virus DNA in saliva, blood serum and peripheral blood cells in patients with nasopharyngealcarcinoma. Chin J Otorhinolaryngol Skull Base Surg, 18, 24-7.
33. Zhang Y, Gao HY, Feng HX, et al (2004). Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal Carcinoma. Natl Med J Chin, 84, 982-6.
34. Zhu HF, He X (2012). Significance of detecting plasma EBV DNA and VCA-IgA in patients with nasopharyngeal carcinoma. J Chin Oncol, 18, 111-3.
35. Zong YS, Sham JS, Ng MH, et al (1992). Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer, 69, 3-7.